Skip to main content
SpringerLink
Log in

Molecular Imaging

  • Chapter
  • First Online:
Nuclear Medicine in Oncology

Abstract

The most prominent metabolic alteration in cancer is a high rate of glycolysis. Liking glucose metabolism, lipid metabolism is also pivotal for tumor proliferation, energy storage, and the generation of signaling molecules. Metabolic imaging of fatty acid can visualize the lipid metabolism of the tumor in vivo by PET/CT, which now plays an important role in the diagnosing and staging for tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66(12):5977–5980

    CAS  PubMed  Google Scholar 

  2. Mori N, Wildes F, Takagi T, Glunde K, Bhujwalla ZM (2016) The tumor microenvironment modulates choline and lipid metabolism. Front Oncol 6:262. https://doi.org/10.3389/fonc.2016.00262.eCollection

    Article  PubMed  PubMed Central  Google Scholar 

  3. Kolthammer JA, Corn DJ, Tenley N, Wu C et al (2011) PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging 38(7):1248–1256

    CAS  PubMed  Google Scholar 

  4. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM (2013) The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64(1):106–117

    PubMed  Google Scholar 

  5. Evangelista L, Guttilla A, Zattoni F, Muzzio PC, Zattoni F (2013) Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. Eur Urol 63(6):1040–1048

    PubMed  Google Scholar 

  6. Graziani T, Ceci F, Castellucci P, Polverari G et al (2016) (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series. Eur J Nucl Med Mol Imaging 43(11):1971–1979

    CAS  PubMed  Google Scholar 

  7. Yamamoto Y, Nishiyama Y, Kameyama R, Okano K et al (2008) Detection of hepatocellular carcinoma using 11C-choline PET: comparison with 18F-FDG PET. J Nucl Med 49(8):1245–1248

    PubMed  Google Scholar 

  8. Mena E, Turkbey B, Mani H, Adler S et al (2012) 11C-Acetate PET/CT in localized prostate cancer: a study with MRI and histopathologic correlation. J Nucl Med 53(4):538–545

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Ho CL, Yu SC, Yeung DW (2003) 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44(2):213–221

    PubMed  Google Scholar 

  10. Park JW, Kim JH, Kim SK, Kang KW et al (2008) A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 49(12):1912–1921

    PubMed  Google Scholar 

  11. Cheung TT, Ho CL, Lo CM, Chen S et al (2013) 11C-acetate and 18F-FDG PET/CT for clinical staging and selection of patients with hepatocellular carcinoma for liver transplantation on the basis of Milan criteria: surgeon’s perspective. J Nucl Med 54(2):192–200

    CAS  PubMed  Google Scholar 

  12. Washburn LC, Sun TT, Anon JB, Hayes RL (1978) Effect of structure on tumor specificity of alicyclic alpha-amino acids. Cancer Res 38:2271–2273

    CAS  PubMed  Google Scholar 

  13. De Vis K, Schelstraete K, Deman J, Vermeulen FL, Sambre J, Goethals P, Van Haver D, Slegers G, Vandecasteele C, De Schryver A (1987) Clinical comparison of 11C-ACPC (aminocyclopentane carboxylic acid) and 13N-ammonia as tumour tracers. Acta Oncol 26:105–111

    PubMed  Google Scholar 

  14. Ho CL, Chen S, Yeung DW, Cheng TK (2007) Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48(6):902–909

    CAS  PubMed  Google Scholar 

  15. Prenant C, Theobald A, Haberkorn U, Bellemann ME, Weber K, Oberdorfer F (1996) Feasibility of labeled alpha-acetamido-aminoisobutyric acid as new tracer compound for kinetic labeling of neutral amino acid transport: preparation of alpha-(N-[1-11C]acetyl)- and alpha-(N-[1-14C]acetyl)-aminoisobutyric acid. Nucl Med Biol 23:359–363

    CAS  PubMed  Google Scholar 

  16. Nakagawa M, Kuwabara Y, Sasaki M, Koga H, Chen T, Kaneko O, Hayashi K, Morioka T, Masuda K (2002) 11C-methionine uptake in cerebrovascular disease: a comparison with 18F-fDG PET and 99mTc-HMPAO SPECT. Ann Nucl Med 16:207–211

    CAS  PubMed  Google Scholar 

  17. Tsuyuguchi N, Takami T, Sunada I, Iwai Y, Yamanaka K, Tanaka K, Nishikawa M, Ohata K, Torii K, Morino M, Nishio A, Hara M (2004) Methionine positron emission tomography for differentiation of recurrent brain tumor and radiation necrosis after stereotactic radiosurgery--in malignant glioma. Ann Nucl Med 18:291–296

    CAS  PubMed  Google Scholar 

  18. Minamimoto R, Saginoya T, Kondo C, Tomura N, Ito K, Matsuo Y, Matsunaga S, Shuto T, Akabane A, Miyata Y, Sakai S, Kubota K (2015) Differentiation of brain tumor recurrence from post-radiotherapy necrosis with 11C-methionine PET: visual assessment versus quantitative assessment. PLoS One 10:e0132515

    PubMed  PubMed Central  Google Scholar 

  19. Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294

    CAS  PubMed  Google Scholar 

  20. Lau EW, Drummond KJ, Ware RE, Drummond E, Hogg A, Ryan G, Grigg A, Callahan J, Hicks RJ (2010) Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci 17:43–49

    PubMed  Google Scholar 

  21. Dunet V, Rossier C, Buck A, Stupp R, Prior JO (2012) Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and metaanalysis. J Nucl Med 53:207–214

    CAS  PubMed  Google Scholar 

  22. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C, Kemp BJ, Grams MP, Morris JM, Hoover JM, Hu LS, Sarkaria JN, Brinkmann DH (2013) Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol 15:1058–1067

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Juhasz C, Dwivedi S, Kamson DO, Michelhaugh SK, Mittal S (2014) Comparison of amino acid positron emission tomographic radiotracers for molecular imaging of primary and metastatic brain tumors. Mol Imaging 13

    Google Scholar 

  24. Zhu L, Ploessl K, Zhou R, Mankoff D, Kung HF (2017) Metabolic imaging of glutamine in cancer. J Nucl Med 58:533–537

    CAS  PubMed  PubMed Central  Google Scholar 

  25. Koopmans KP, Glaudemans AW (2014) Other PET tracers for neuroendocrine tumors. PET Clin 9:57–62

    PubMed  Google Scholar 

  26. Toumpanakis C, Kim MK, Rinke A, Bergestuen DS, Thirlwell C, Khan MS, Salazar R, Oberg K (2014) Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors. Neuroendocrinology 99:63–74

    CAS  PubMed  Google Scholar 

  27. Huang C, McConathy J (2013) Fluorine-18 labeled amino acids for oncologic imaging with positron emission tomography. Curr Top Med Chem 13:871–891

    CAS  PubMed  Google Scholar 

  28. Baek S, Choi CM, Ahn SH, Lee JW, Gong G, Ryu JS, Oh SJ, Bacher-Stier C, Fels L, Koglin N, Hultsch C, Schatz CA, Dinkelborg LM, Mittra ES, Gambhir SS, Moon DH (2012) Exploratory clinical trial of (4S)-4-(3-[18F]fluoropropyl)-L-glutamate for imaging xC- transporter using positron emission tomography in patients with non-small cell lung or breast cancer. Clin Cancer Res 18:5427–5437

    CAS  PubMed  Google Scholar 

  29. Savir-Baruch B, Zanoni L, Schuster DM (2018) Imaging of prostate cancer using fluciclovine. Urol Clin North Am 45:489–502

    PubMed  Google Scholar 

  30. Picchio M, Mapelli P, Panebianco V, Castellucci P, Incerti E, Briganti A, Gandaglia G, Kirienko M, Barchetti F, Nanni C, Montorsi F, Gianolli L, Fanti S (2015) Imaging biomarkers in prostate cancer: role of PET/CT and MRI. Eur J Nucl Med Mol Imaging 42:644–655

    CAS  PubMed  Google Scholar 

  31. Morita M, Higuchi T, Achmad A, Tokue A, Arisaka Y, Tsushima Y (2013) Complementary roles of tumour specific PET tracer (1)(8)F-FAMT to (1)(8)F-FDG PET/CT for the assessment of bone metastasis. Eur J Nucl Med Mol Imaging 40:1672–1681

    CAS  PubMed  Google Scholar 

  32. Burger IA, Zitzmann-Kolbe S, Pruim J, Friebe M, Graham K, Stephens A, Dinkelborg L, Kowal K, Schibli R, Luurtsema G, Maas B, Horn-Tutic M, Haerle SK, Wiegers J, Schaefer NG, Hany TF, von Schulthess GK (2014) First clinical results of (D)-18F-fluoromethyltyrosine (BAY 86-9596) PET/CT in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. J Nucl Med 55:1778–1785

    CAS  PubMed  Google Scholar 

  33. Voet D, Voet J, Pratt C (2008) Fundamentals of biochemistry: life at the molecular level, 3rd edn. Wiley, Hoboken, NJ. ISBN 9780470129302

    Google Scholar 

  34. “Nucleotide metabolism”. The medical biochemistry. Accessed 20 Oct 2014

    Google Scholar 

  35. Ammann AJ (1985) Purine nucleotide imbalance in immunodeficiency disorders. Basic Life Sci 31:487–502

    CAS  PubMed  Google Scholar 

  36. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H (2003) Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34:440–445

    CAS  PubMed  Google Scholar 

  37. El-Hattab AW, Scaglia F (2013) Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics 10:186–198

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Dang CV (2012) Links between metabolism and cancer. Genes Dev 26:877–890

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Hartman SC, Buchanan JM (1959) Nucleic acids, purines, pyrimidines (nucleotide synthesis). Annu Rev Biochem 28:365–410

    CAS  PubMed  Google Scholar 

  40. Reichard P (1988) Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem 57:349–374

    CAS  PubMed  Google Scholar 

  41. Nordlund P, Reichard P (2006) Ribonucleotide reductases. Annu Rev Biochem 75:681–706

    CAS  PubMed  Google Scholar 

  42. Anglana M, Apiou F, Bensimon A, Debatisse M (2003) Dynamics of DNA replication in mammalian somatic cells: nucleotide pool modulates origin choice and interorigin spacing. Cell 114:385–394

    CAS  PubMed  Google Scholar 

  43. Engstrom Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B (1985) Cell cycle-dependent expression of mammalian ribonucleotide reductase. Differential regulation of the two subunits. J Biol Chem 260:9114–9116

    CAS  PubMed  Google Scholar 

  44. Hakansson P, Hofer A, Thelander L (2006) Regulation of mammalian ribonucleotide reduction and dNTP pools after DNA damage and in resting cells. J Biol Chem 281:7834–7841

    CAS  PubMed  Google Scholar 

  45. Weber WA, Czernin J, Phelps ME, Herschman HR (2008) Technology insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract 5:44–54

    CAS  Google Scholar 

  46. Gayed I et al (2004) The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 45:17–21

    CAS  PubMed  Google Scholar 

  47. Evilevitch V et al (2008) Reduction of glucose metabolic activity is more accurate than change in size at predicting histopathologic response to neoadjuvant therapy in high-grade soft-tissue sarcomas. Clin Cancer Res 14:715–720

    CAS  PubMed  Google Scholar 

  48. Dose Schwarz J et al (2005) Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET. J Nucl Med 46:1144–1150

    PubMed  Google Scholar 

  49. Weber WA et al (2003) Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 21:2651–2657

    CAS  PubMed  Google Scholar 

  50. Lordick F et al (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805

    PubMed  Google Scholar 

  51. Peterson LM et al (2008) Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J Nucl Med 49:367–374

    PubMed  Google Scholar 

  52. Cheng Z et al (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 49:804–813

    CAS  PubMed  PubMed Central  Google Scholar 

  53. Schelhaas S et al (2017) Preclinical applications of 3′-Deoxy-3′-[18F] fluorothymidine in oncology - a systematic review. Theranostics 7(1):40–50

    CAS  PubMed  PubMed Central  Google Scholar 

  54. Lee JT et al (2012) Stratification of nucleoside analog chemotherapy using 1-(2′-Deoxy-2′-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2′-Deoxy-2′-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET. J Nucl Med 53(2):275–280

    CAS  PubMed  PubMed Central  Google Scholar 

  55. Nair-Gill E et al (2010) PET probes for distinct metabolic pathways have different cell specificities during immune responses in mice. J Clin Invest 120(6):2005–2015

    CAS  PubMed  PubMed Central  Google Scholar 

  56. Ishibashi K et al (2017) PET imaging of 18F-FDG, 11C-methionine, 11C-flumazenil, and 11C-4DST in progressive multifocal leukoencephalopathy. Intern Med 56(10):1219–1223

    PubMed  PubMed Central  Google Scholar 

  57. Lopci E, Grassi I, Chiti A et al (2014) PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging 4(4):365–384

    PubMed  PubMed Central  Google Scholar 

  58. Urtasun RC, Parliament MB, McEwan AJ et al (1996) Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. Br J Cancer Suppl 27:S209–S212

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Mees G, Dierckx R, Vangestel C et al (2009) Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 36:1674–1686

    CAS  PubMed  PubMed Central  Google Scholar 

  60. Cook GJ, Houston S, Barrington SF et al (1998) Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG. J Nucl Med 39:99–103

    CAS  PubMed  Google Scholar 

  61. Li L, Yu J, Xing L et al (2006) Serial hypoxia imaging with 99mTc-HL91 SPE- CT to predict radiotherapy response in non-small cell lung cancer. Am J Clin Oncol 29(6):628–633

    PubMed  Google Scholar 

  62. Lee ST, Scott AM (2007) Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 37:451–461

    PubMed  Google Scholar 

  63. Servagi-Vernat S, Differding S, Hanin FX et al (2014) A prospective clinical study of 18 F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging 41(8):1544–1552

    CAS  PubMed  Google Scholar 

  64. Horsman MR, Overgaard J (2016) The impact of hypoxia and its modification of the outcome of radiotherapy. J Radiat Res 57(Suppl 1):i90–i98

    PubMed  PubMed Central  Google Scholar 

  65. Tamaki N, Hirata K (2016) Tumor hypoxia: a new PET imaging biomarker in clinical oncology. Int J Clin Oncol 21(4):619–625

    CAS  PubMed  Google Scholar 

  66. Hendrickson K, Phillips M, Smith W et al (2011) Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guidingintensity modulated radiation therapy in overcominghypoxia-induced treatment resistance. Radiother Oncol 101:369–375

    PubMed  PubMed Central  Google Scholar 

  67. Lee CT, Boss MK, Dewhirst MW (2014) Imaging tumor hypoxia to advance radiation oncology. Antioxid Redox Signal 21(2):313–337

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Lee NY, Mechalakos JG, Nehmeh S et al (2008) Fluorine-18-labeled fluoromisonidazole positron emission andcomputed tomography-guided intensity-modulated radiotherapyfor head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 70:2–13

    CAS  PubMed  Google Scholar 

  69. Nehmeh SA, Lee NY, Schroder H et al (2008) Reproducibility of intratumordistribution of (18)F-fluoromisonidazole in head and neckcancer. Int J Radiat Oncol Biol Phys 70:235–242

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Lin Z, Mechalakos J, Nehmeh S et al (2008) The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 70:1219–1228

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nanfang PET center, Nanfang Hospital, Southern Medical University, Guangzhou, P. R. China

    Hubing Wu

  2. Department of Nuclear Medicine, RenJi Hospital, School of Medicine, Shanghai JiaoTong University, Shanghai, P. R. China

    DeWei Tang & XiaoPing Zhao

  3. Department of Nuclear Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, P. R. China

    Gengbiao Yuan

  4. Department of Nuclear Medicine, Zhongshan Hospital Xiamen University, Xiamen, P. R. China

    Xinhui Su

Authors
  1. Hubing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. DeWei Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. XiaoPing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gengbiao Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xinhui Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Shanghai Key Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China

    Gang Huang

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd. and Shanghai Jiao Tong University Press

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wu, H., Tang, D., Zhao, X., Yuan, G., Su, X. (2019). Molecular Imaging. In: Huang, G. (eds) Nuclear Medicine in Oncology. Springer, Singapore. https://doi.org/10.1007/978-981-13-7458-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-7458-6_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-7457-9

  • Online ISBN: 978-981-13-7458-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation